|
(6) Molecular mechanisms explaining premalignant changes in the etiology of melanoma
|
5R21CA208736-02
|
$180,000
|
MURPH, MANDI
|
UNIVERSITY OF GEORGIA
|
|
(8) Genetics of Immune Related Adverse Events and Response to Immunotherapy
|
1R01CA227466-01
|
$699,062
|
ZIV, ELAD
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
(8) Genomic determinants of the T-cell regulome in immune checkpoint blockade
|
1R01CA227505-01
|
$620,860
|
KIRCHHOFF, TOMAS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors
|
1R01CA231291-01
|
$533,211
|
WELLSTEIN, ANTON
|
GEORGETOWN UNIVERSITY
|
|
(PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltration
|
5R01CA205965-02
|
$640,839
|
CURIEL, TYLER
|
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
|
|
(PQ10) Enhancing responses to immune checkpoint blockade in melanoma via modulation of the microbiome
|
1R01CA219896-01A1
|
$429,943
|
WARGO, JENNIFER
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
(PQ10) The impact of the gut microbiome on the anti-tumor effects of radiotherapy
|
1R01CA219871-01A1
|
$451,326
|
FACCIABENE, ANDREA
|
UNIVERSITY OF PENNSYLVANIA
|
|
(PQ2) PD-L1/PD-1 signals in aged hosts undergoing cancer immunotherapy
|
1R01CA231325-01
|
$572,540
|
CURIEL, TYLER
|
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
|
|
(PQ3) The role of damaged DNA in inter-individual variation of tumor immunity
|
5R01CA208756-03
|
$518,165
|
HACOHEN, NIR
|
BROAD INSTITUTE, INC.
|
|
(PQ5) Mitochondrial Heterogeneity in Melanoma Tumor and Immune Responses
|
1R01CA216101-01A1
|
$670,933
|
SHADEL, GERALD
|
SALK INSTITUTE FOR BIOLOGICAL STUDIES
|
|
(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition
|
1R01CA231295-01
|
$481,288
|
OSMAN, IMAN
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
1/2 SDSU/UCSD Cancer Center Comprehensive Partnership
|
5U54CA132379-09
|
$1,304,869
|
MARTINEZ, MARIA
|
UNIVERSITY OF CALIFORNIA, SAN DIEGO
|
|
2/2 Ponce School of Medicine-Moffitt Cancer Center Partnership
|
5U54CA163068-07
|
$1,751,252
|
MUNOZ-ANTONIA, TERESITA
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
3D Models of Immunotherapy
|
5U01CA214369-02
|
$729,562
|
MOONEY, DAVID
|
HARVARD UNIVERSITY
|
|
A CD47-blocking oncolytic vaccinia virus for cancer therapy
|
5F30CA203270-03
|
$44,524
|
CAO, FELICIA
|
BAYLOR COLLEGE OF MEDICINE
|
|
A comparison of interventions to teach patients skin self-examination
|
5R01CA154908-08
|
$724,343
|
ROBINSON, JUNE
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
A druggable dependency in low-MITF/high-AXL melanoma: preclinical efficacy and mechanism of action in a key treatment-resistant subclass.
|
1R01CA222871-01
|
$373,547
|
FISHER, DAVID
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
A genomewide discovery of chemoresistance-associated noncoding RNAs in human cancers
|
1R21CA226303-01
|
$176,175
|
HE, TONG-CHUAN
|
UNIVERSITY OF CHICAGO
|
|
A germline variant that predicts and modulates the response of melanoma to immunotherapy
|
5R21CA209309-02
|
$237,724
|
OSMAN, IMAN
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
A High-Throughput Model for Human Melanoma
|
5R01CA121118-10
|
$247,340
|
HOLMEN, SHERI
|
UNIVERSITY OF UTAH
|
|
A high-throughput platform for neo-antigen based cancer immunotherapy
|
1R43CA233120-01
|
$299,917
|
XIAO, JUN
|
IMMUDX, LLC
|
|
A Molecular Diagnostic Assay for Accurately Differentiating Melanoma from Benign Lesions
|
1R44CA228897-01
|
$299,244
|
HACHEY, DAVID
|
FRONTIER DIAGNOSTICS, LLC
|
|
A NOVEL DRUGGABLE GENETIC VULNERABILITY PATHWAY IN MELANOMA
|
5R01CA200919-03
|
$383,156
|
WAJAPEYEE, NARENDRA
|
YALE UNIVERSITY
|
|
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
|
4R44CA217591-02
|
$1,125,311
|
KAHN, STUART
|
SYNTRIX BIOSYSTEMS, INC.
|
|
A plasticity and reprogramming paradigm for therapy resistance at the single cell level
|
1U01CA227550-01
|
$598,501
|
RAJ, ARJUN
|
UNIVERSITY OF PENNSYLVANIA
|
|
A real-time, cost-effective, accurate UV measurement and sun protection system to prevent and reduce the incidence of sunburn in high-risk consumers.
|
4R44CA224658-02
|
$686,491
|
MEITL, MATTHEW
|
WEARIFI, INC.
|
|
A role for c-Abl/Arg in melanoma progression
|
3R01CA166499-05S1
|
$51,515
|
PLATTNER, RINA
|
UNIVERSITY OF KENTUCKY
|
|
A Self-Regulation Approach to an Indoor Tanning Intervention for Frequent Users
|
5K07CA175115-05
|
$76,512
|
STAPLETON, JEROD
|
RBHS -CANCER INSTITUTE OF NEW JERSEY
|
|
A-to-I microRNA Editing and Melanoma Metastasis
|
1R21CA219958-01A1
|
$208,800
|
BARELI, MENASHE
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma
|
1R01CA229851-01
|
$398,271
|
SULLIVAN, RYAN
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-42S1
|
$244,519
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-42S2
|
$55,717
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-42S3
|
$65,235
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
5P30CA016520-42
|
$7,716,753
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Adaptive regulation of cancer cell fate following oncogene inhibition
|
5R00CA194163-04
|
$249,000
|
FALLAHI-SICHANI, MOHAMMAD
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Adoptive Cell Therapy with Rejuvenated Antigen-Specific T Cells
|
5K08CA197966-05
|
$174,960
|
ITO, FUMITO
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Adoptive Cell Transfer Immunotherapy of Cancer
|
ZIA BC 010984
|
$1,860,145
|
Rosenberg, Steven
|
CCR (NCI)
|
|
An Engineered Nanoimmunotherapy for Melanoma
|
1R41CA217294-01A1
|
$200,001
|
SWEENEY, ELIZABETH
|
IMMUNOBLUE, LLC
|
|
An ESC-GEMM platform for rapid melanoma mouse modeling
|
1R03CA227349-01
|
$86,000
|
KARRETH, FLORIAN
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
An innate immune checkpoint in cancer immunotherapy
|
5R01CA212376-02
|
$468,186
|
ROTHLIN, CARLA
|
YALE UNIVERSITY
|
|
An innate immune checkpoint in cancer immunotherapy.
|
3R01CA212376-02S1
|
$113,240
|
ROTHLIN, CARLA
|
YALE UNIVERSITY
|
|
An Internet-Based Behavioral Intervention for Individuals Diagnosed with Melanoma
|
5R01CA171666-05
|
$483,098
|
COUPS, ELLIOT
|
RBHS -CANCER INSTITUTE OF NEW JERSEY
|
|
Anatomic Pathology Residency Program
|
ZIE BC 011384
|
$1,537,925
|
Barr, Frederic
|
CCR (NCI)
|
|
Animal Model and Genotyping Core Support Facility
|
ZIC BC 011047
|
$775,353
|
DuBois, Wendy
|
CCR (NCI)
|
|
Anti-CD38 targeted alpha emitter radioimmunotherapy to eliminate multiple myeloma
|
5R01CA205248-02
|
$656,744
|
GREEN, DAMIAN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Antibodies to melanoma vaccine peptides
|
5R03CA219715-02
|
$80,750
|
SLINGLUFF, CRAIG
|
UNIVERSITY OF VIRGINIA
|
|
Anticancer Strategies Targeting the Autotaxin-LPA Receptor Axis
|
2R01CA092160-16A1
|
$298,443
|
TIGYI, GABOR
|
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
|
|
Antigen-specific T-cell Activation, Application to Vaccines for Cancer and AID
|
ZIA SC 004020
|
$3,223,418
|
Berzofsky, Jay
|
CCR (NCI)
|
|
Assessing the effect of anti-PD-1/PD-L1 agents on tumoricidal efficacy of secretory TRAIL-armed NK cells
|
5R03CA205267-02
|
$77,959
|
LEE, YONG
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Assisted Network-based Analysis of Cancer Gene Expression Studies
|
5R03CA216017-02
|
$83,750
|
MA, SHUANGGE
|
YALE UNIVERSITY
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|